{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Top officials of the Food and Drug Administration acknowledged for the first time on Monday that antidepressants appeared to lead some children and teenagers to become suicidal. Dr. Robert Temple, director of the F.D.A.'s office of medical policy, said after an emotional public hearing here that analyses of 15 clinical trials, some of which were hidden for years from the public by the drug companies that sponsored them, showed a consistent link with suicidal behavior.", "headline": {"main": "F.D.A. LINKS DRUGS TO BEING SUICIDAL"}, "abstract": "Food and Drug Administration officials acknowledge for first time that antidepressants appear to lead some children and teenagers to become suicidal; Dr Robert Temple, director of FDA's office of medical policy, says analyses of 15 clinical trials, some of which were hidden for years from public by drug companies that sponsored them, show consistent link with suicidal behavior; FDA's acknowledgement of link comes year after it suppressed similar conclusions of its own drug-safety analyst Dr Andrew Mosholder, calling them unreliable; agency hired researchers at Columbia Univ to re-analyze same data, and that study reached conclusions nearly identical to Mosholder's; Temple's announcement is made at emotional public hearing at which family members of suicide victims angrily denounce agency officials for delay in admitting risk of antidepressants in children; issue roils agency and is likely to transform way drug industry markets its products; committees in House and Senate begin investigations following disclosure that Mosholder's analysis had been suppressed (M)", "print_page": "1", "word_count": 1148, "_id": "4fd23e528eb7c8105d7d49b8", "snippet": "Top officials acknowledged for the first time that antidepressants appeared to lead some children to become suicidal.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/14/health/14depress.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "TEMPLE, ROBERT"}, {"name": "persons", "value": "MOSHOLDER, ANDREW D"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "COLUMBIA UNIVERSITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-09-14T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "Interview", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "In many ways, Dr. Marcia Angell is an unlikely muckraker. A pathologist by training, she is the former editor in chief of The New England Journal of Medicine. She is also a senior lecturer at Harvard Medical School. But just days short of her 65th birthday and her first Social Security check, Dr. Angell is taking on the American pharmaceutical industry with a new book, ''The Truth About the Drug Companies: How They Deceive Us and What to Do About It'' (Random House).''I don't worry about labels,'' Dr. Angell said in an interview at the Hotel Monaco, where she stopped during a book tour.", "headline": {"main": "A Doctor Puts the Drug Industry Under a Microscope", "kicker": "A CONVERSATION WITH: MARCIA ANGELL"}, "abstract": "Interview with Marcia Angell, former editor in chief of New England Journal of Medicine and author of recent book The Truth About the Drug Companies: How They Deceive Us and What to Do About It, discusses high pricing in drug industry and conflict of interest issues in drug research; suggests that pharmaceutical companies use minor variations on old drugs to increase profits without benefit to consumer; photo (M)", "print_page": "5", "word_count": 1406, "_id": "4fd247ef8eb7c8105d7e3c1e", "snippet": "Dr. Marcia Angell, a pathologist and former editor of The New England Journal of Medicine, is taking on the American pharmaceutical industry.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/14/health/policy/14conv.html", "multimedia": [{"url": "images/2004/09/14/science/14conv.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/09/14/science/14conv.75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "TRUTH ABOUT THE DRUG COMPANIES, THE (BOOK)"}, {"name": "persons", "value": "ANGELL, MARCIA"}, {"name": "organizations", "value": "NEW ENGLAND JOURNAL OF MEDICINE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "BOOKS AND LITERATURE"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Claudia", "rank": 1, "lastname": "DREIFUS"}], "original": "By CLAUDIA DREIFUS"}, "document_type": "article", "pub_date": "2004-09-14T00:00:00Z", "section_name": "Health; Books"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Medicare has suddenly emerged as a volatile issue in this year's elections, as Democrats are vowing to roll back a sharp increase in premiums announced this month and the Bush campaign is seeking to blame lawmakers, including Senator John Kerry, for the rise. The trading of accusations reflects efforts by both parties to seek advantage with older voters.", "headline": {"main": "Medicare Costs Are New Focus for Candidates"}, "abstract": "Medicare emerges as volatile election issue, as Democrats vow to roll back sharp increase in premiums and Bush campaign seeks to blame lawmakers, including Sen John Kerry, for rise; if Congress does not intervene by passing legislation, premiums will rise in January to $78.20 month, 56 percent incrase over premiums in 2001; Democrats and AARP, group representing older Americans, say higher costs strengthen case for importing inexpensive drugs from Canada, move adamantly opposed by White House, Republican leaders in Congress and drug companies; Republicans had hoped to emphasize new law signed by Pres Bush in December that adds drug benefits to Medicare program, but law has met mixed reviews; photo (M)", "print_page": "1", "word_count": 1386, "_id": "4fd259a88eb7c8105d805d8b", "snippet": "Democrats are vowing to roll back premium increases, and the Bush campaign is seeking to blame lawmakers for the rise.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/12/politics/campaign/12medicare.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "KERRY, JOHN"}, {"name": "persons", "value": "KERRY, JOHN F"}, {"name": "glocations", "value": "CANADA"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "DEMOCRATIC PARTY"}, {"name": "organizations", "value": "REPUBLICAN PARTY"}, {"name": "organizations", "value": "AARP"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "POLITICS AND GOVERNMENT"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "PRESIDENTIAL ELECTION OF 2004"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Robert", "rank": 1, "lastname": "PEAR"}, {"organization": "", "role": "reported", "firstname": "Carl", "rank": 2, "lastname": "HULSE"}], "original": "By ROBERT PEAR and CARL HULSE"}, "document_type": "article", "pub_date": "2004-09-12T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A group of leading medical journals yesterday released a plan to stop publishing the results of clinical trials unless a test is registered at its outset in a public database. The plan, news of which had emerged earlier this week, represents a major policy shift by influential gatekeepers in the medical profession as they seek to increase the distribution and accuracy of research data. Too often, experts contend, medical studies with dramatic findings are highlighted as breakthroughs, while inconclusive or negative tests of the same treatment are ignored or undisclosed.", "headline": {"main": "Major Medical Journals Will Require Registration of Trials"}, "abstract": "International Committee of Medical Journal Editors releases plan to stop publishing results of clinical trials unles test is registered at its outset in public database; plan represents major policy shift by influential overseers in medical profession as they seek to increase distribution and accuracy of research data; group includes such high-profile publications as Journal of American Medical Association , New England Journal of Medicine, The Lancet and Annals of Internal Medicine; many academic researchers and others applaud decision by editors as major step in promoting greater disclosure by companies and research institutions about tests they sponsor (M)", "print_page": "11", "word_count": 1029, "_id": "4fd2a4808eb7c8105d88a7f6", "snippet": "A group of leading medical journals elaborated on their plan to soon stop publishing the results of clinical trials unless a test is registered at its outset in a public database.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/09/business/09registry.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "LANCET"}, {"name": "organizations", "value": "AMERICAN MEDICAL ASSN"}, {"name": "organizations", "value": "INTERNATIONAL COMMITTEE OF MEDICAL JOURNAL EDITORS"}, {"name": "organizations", "value": "NEW ENGLAND JOURNAL OF MEDICINE"}, {"name": "organizations", "value": "JOURNAL OF AMERICAN MEDICAL ASSN"}, {"name": "organizations", "value": "ANNALS OF INTERNAL MEDICINE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Barry", "rank": 1, "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2004-09-09T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 4, "offset": 0, "time": 90}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}